Home » Topics » BioWorld Science

BioWorld Science
RSS

Aptose exercises option to license CrystalGenomics' CG-806

May 8, 2018

FDA approves Myrbetriq in combination with solifenacin for overactive bladder

May 8, 2018

QuANTUM-R study of quizartinib in FLT3-ITD-mutated AML meets primary endpoint

May 8, 2018

FDA approves Darzalex with VMP for newly diagnosed multiple myeloma

May 8, 2018

E.U. funding supports development of The Cell Factory's second-generation EV drug for stroke

May 8, 2018

Human papillomavirus cancer vaccine utilizes CD11b-targeting nanobodies

May 8, 2018

Pfizer nominates final hepatic targets under collaboration with Wave Life Sciences

May 8, 2018

CARB-X supports Melinta's development of pyrrolocytosine compounds

May 8, 2018

EMA gives positive scientific advice on development plan and regulatory pathway for AM-111

May 8, 2018

Secarna Pharmaceuticals patents novel anti-CD39 immunosuppression-reverting oligonucleotides

May 8, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...